Delivery Order SPE2DB24D1205-SPE2DB25FCXMB
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Xyosted 75 mg/0.5 mL auto-injector vials by the Defense Logistics Agency on September 9, 2025. The contract carries a ceiling value of $3,766.19 with a firm fixed-price structure and an ultimate completion date of September 10, 2025. This is a non-set-aside award issued under a competitive procurement process, reflecting the company's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector vials, with a contract ceiling value of $1,617.32 and an ultimate completion date of November 7, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a small-value pharmaceutical procurement fulfilled through performance in Conshohocken, Pennsylvania. The award was made competitively with no set-aside designation and is classified as a child contract under a larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $6,914.68 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,146.22 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies. This is a firm fixed price delivery order with no set-aside designation, issued on September 19, 2025, with a completion date of September 22, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units with a ceiling value of $1,264.81. This non-set-aside contract, awarded on June 10, 2025, with an ultimate completion date of June 11, 2025, utilizes firm fixed-price pricing and is issued under a competitive delivery order mechanism. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location....
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,375.49. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. Performance will be executed from the company's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order represents a...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXMBDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,547.87 by the Defense Logistics Agency on June 6, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract represents a firm fixed-price delivery order with an ultimate completion date of June 9, 2025, and will be performed at the company's Corporate Office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and serves as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor headquartered in Pennsylvania that supplies a comprehensive range of medications, vaccines, and medical devices to support military and veteran healthcare systems. This delivery order falls under the company's prime IDC with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which enables the company to supply pharmaceutical products and medical supplies globally to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's track record demonstrates consistent capability in fulfilling federal medical procurement requirements through competitive award processes across multiple therapeutic domains and transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 6/6/25 |